Gathering in Japan, Exploring New Opportunities for Global Pharma — Sichuan Elixir Pharmaceutical Debuts at CPHI Japan 2026
Gathering in Japan, Exploring New Opportunities for Global Pharma — Sichuan Elixir Pharmaceutical Debuts at CPHI Japan 2026
Exhibition Information
Exhibition: CPHI Japan 2026
Date: April 21 – 23, 2026
Venue: Tokyo, Japan
Booth No.: 3G-29
CPHI Japan 2026, an annual flagship event for the global pharmaceutical industry, grandly kicked off in Tokyo from April 21 to 23, 2026. Sichuan Elixir Pharmaceutical Co., Ltd. showcased its active pharmaceutical ingredient (API) and pharmaceutical preparation businesses at the event, engaging in in-depth exchanges with clients across the Asia-Pacific region and worldwide to explore potential cooperation.
As an international pharmaceutical enterprise driven by a dual development strategy of API + Pharmaceutical Preparations, Elixir focuses on the R&D, production and global registration of naturally-derived and anti-tumor APIs. Meanwhile, it has built a full-spectrum service system covering pharmaceutical preparation License-in, License-out and pharmaceutical CRO services.
✅ API Business: High-potency anti-tumor APIs and specialty intermediates manufactured in compliance with cGMP and international pharmacopoeia standards, supporting registration in China, the US, Europe, Japan and other regions.
✅ Pharmaceutical Preparation License-in: Facilitate the rapid introduction of high-quality overseas pharmaceutical products into the domestic market, delivering end-to-end support from clinical research, registration to commercial launch.
✅ Pharmaceutical Preparation License-out: Authorize overseas rights of self-developed and co-developed pharmaceutical preparations to international partners to maximize the global value of products.
✅ Pharmaceutical CRO Services: One-stop R&D outsourcing services including formula development, process optimization, quality research, bioequivalence (BE) study, consistency evaluation and international registration application, supporting multi-jurisdiction filings in China, the US, Europe and Japan.
During the exhibition, the Elixir team held multiple one-on-one in-depth discussions with new and existing clients as well as industry peers from around the globe. The team highlighted the company’s core strengths and successful cases in compliant API supply chain, pharmaceutical business development (License-in/out) and integrated pharmaceutical CRO services. Boasting a professional technical team, complete international registration qualifications (PMDA, FDA, EDQM, NMPA) and rich project management experience, the company won high recognition and definite cooperation intentions from numerous clients.
Going forward, adhering to the development philosophy of Rooted in APIs, Empowered by Preparations, Driven by Innovation, and Seeking Win-Win Cooperation Globally, the company will further expand core businesses including API export, pharmaceutical preparation License-in & License-out, and pharmaceutical CRO services. With more professional expertise and superior products and services, Elixir will join hands with global partners to create a new chapter for high-quality development of the pharmaceutical industry.
